Abstract
We retrospectively assessed morphologic and cytogenetic responses to 5-azacytidine and decitabine in a cohort of 42 adult therapy-related myelodysplastic syndromes (tMDS) patients treated at Memorial Sloan-Kettering Cancer Center and in 2 industry-sponsored decitabine trials (D0007 and DACO-020). The overall response rate (complete remission. +. marrow CR. +. hematologic improvement) was 38%, including 6 patients with complete remission (14%), 6 with marrow CR with or without hematologic improvement (14%), and 4 with hematologic improvement alone (10%). We conclude that DNA methyltransferase inhibitors showed activity in tMDS that is roughly comparable to that seen in de novo MDS.
| Original language | English |
|---|---|
| Pages (from-to) | 1093-1097 |
| Number of pages | 5 |
| Journal | Leukemia Research |
| Volume | 36 |
| Issue number | 9 |
| DOIs | |
| State | Published - Sep 1 2012 |
| Externally published | Yes |
Fingerprint
Keywords
- 5-Azacytidine
- Decitabine
- Leukemia
- Therapy-related cancer
ASJC Scopus subject areas
- Cancer Research
- Hematology
- Oncology
Cite this
Efficacy of hypomethylating agents in therapy-related myelodysplastic syndromes. / Klimek, Virginia M.; Dolezal, Emily K.; Tees, Michael T.; Devlin, Sean M.; Stein, Karen; Romero, Alejandro; Nimer, Stephen D.
In: Leukemia Research, Vol. 36, No. 9, 01.09.2012, p. 1093-1097.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Efficacy of hypomethylating agents in therapy-related myelodysplastic syndromes
AU - Klimek, Virginia M.
AU - Dolezal, Emily K.
AU - Tees, Michael T.
AU - Devlin, Sean M.
AU - Stein, Karen
AU - Romero, Alejandro
AU - Nimer, Stephen D
PY - 2012/9/1
Y1 - 2012/9/1
N2 - We retrospectively assessed morphologic and cytogenetic responses to 5-azacytidine and decitabine in a cohort of 42 adult therapy-related myelodysplastic syndromes (tMDS) patients treated at Memorial Sloan-Kettering Cancer Center and in 2 industry-sponsored decitabine trials (D0007 and DACO-020). The overall response rate (complete remission. +. marrow CR. +. hematologic improvement) was 38%, including 6 patients with complete remission (14%), 6 with marrow CR with or without hematologic improvement (14%), and 4 with hematologic improvement alone (10%). We conclude that DNA methyltransferase inhibitors showed activity in tMDS that is roughly comparable to that seen in de novo MDS.
AB - We retrospectively assessed morphologic and cytogenetic responses to 5-azacytidine and decitabine in a cohort of 42 adult therapy-related myelodysplastic syndromes (tMDS) patients treated at Memorial Sloan-Kettering Cancer Center and in 2 industry-sponsored decitabine trials (D0007 and DACO-020). The overall response rate (complete remission. +. marrow CR. +. hematologic improvement) was 38%, including 6 patients with complete remission (14%), 6 with marrow CR with or without hematologic improvement (14%), and 4 with hematologic improvement alone (10%). We conclude that DNA methyltransferase inhibitors showed activity in tMDS that is roughly comparable to that seen in de novo MDS.
KW - 5-Azacytidine
KW - Decitabine
KW - Leukemia
KW - Therapy-related cancer
UR - http://www.scopus.com/inward/record.url?scp=84864008372&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84864008372&partnerID=8YFLogxK
U2 - 10.1016/j.leukres.2012.04.025
DO - 10.1016/j.leukres.2012.04.025
M3 - Article
C2 - 22608310
AN - SCOPUS:84864008372
VL - 36
SP - 1093
EP - 1097
JO - Leukemia Research
JF - Leukemia Research
SN - 0145-2126
IS - 9
ER -